WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE MKT:CVRS), a leading developer of precision vascular robotics, today announced the addition of two experienced leaders in the medical device industry to the Company’s management team.

Doug Teany was named Senior Vice President of Research & Development and Operations, effective March 21, 2016. Mr. Teany has an 18-year track record of driving operational excellence in the medical device and pharmaceutical industries. He joins Corindus from East River Consulting Group where he specialized in scaling operations for emerging medical device companies. Previously, Mr. Teany served as Vice President in Boston Scientific’s Research & Development organization, responsible for strategy and operations of its global clinical and preclinical research functions. During his tenure at Boston Scientific, Mr. Teany played a key role in returning the company to profitability, contributing significantly to operating income growth through product development optimization and operational performance improvement. He designed and led numerous organizational transformations, improved operations for multiple large-scale laboratory and research facilities and optimized the performance of pivotal development programs such as the Promus Element™ Stent and Lotus™ Valve TAVI Systems.
Nora Dutta was named Vice President, Human Resources, effective April 25, 2016. Ms. Dutta brings 19 years of human resources experience including organizational development, strategy, recruiting, and employee relations, joining Corindus from AMAG Pharmaceuticals where she served as Senior Director of Human Resources. In that role, she provided strategic leadership on a transformational acquisition, was a member of the senior management team for its Hematology and Oncology Division and lead AMAG’s HR Operations and Recruitment functions. Previously, Ms. Dutta served as a Strategic HR Business Partner to the Global Strategy, Marketing and Business Services functions at Boston Scientific. She was also a key team member on numerous acquisitions and strategic business initiatives over her 8-year tenure with Boston Scientific.
Mr. Teany and Ms. Dutta will be part of the Corindus senior leadership team, reporting directly to Mark Toland, President and Chief Executive Officer.

"We are delighted to bring in two leaders with highly relevant experience and a long track record of successfully building high-performing teams and establishing organizational excellence," said Toland. “We welcome Doug and Nora to our team, and look forward to their many contributions as we enter this next stage of growth."

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic-assisted precision to radial, coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward-Looking Statements

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements regarding:

the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians, and
Corindus entering its next stage of growth.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.

Contacts
Corindus Vascular Robotics
Brett Prince, 508-653-3335 Ext. 231
VP Marketing
Brett.prince@corindus.com
or
Yuliya Kutuzava, 203-504-8230 Ext. 131
corindus@knbcomm.com
or
Investor Contact:
Lynn Pieper Lewis, 415-937-5202
ir@corindus.com